# CDNA — CareDx · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CDNA  
**Sources:** 20  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cdna-caredx-catalysts-narrative-risks-5893

---

# CareDx (CDNA) — Research Snapshot as of 2026-10-03

**Company context:** CareDx is a Nasdaq-listed precision-medicine diagnostics company focused on genomics-based transplant diagnostics, testing services, products, and digital solutions [[20]](https://stockanalysis.com/stocks/cdna/). As of early October 2026 it carries a market capitalization near $3.4–3.5B and trades in the high-$60s (e.g., $67.15 on Oct 2, 2026) [[5]](https://stockanalysis.com/stocks/cdna/forecast/)[[6]](https://tickernerd.com/stock/cdna-forecast/)[[20]](https://stockanalysis.com/stocks/cdna/).

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cdna-caredx-catalysts-narrative-risks-5893 (free to sign up)._
